Boehringer Ingelheim Venture Fund co-led a $13.3m round for the immuno-oncoclogy startup, which was spun out of University of Duisburg-Essen’s and University of Düsseldorf.
Germany-based cancer immunotherapy developer Abalos Therapeutics launched yesterday with €12m ($13.3m) in funding from a series A round co-led by pharmaceutical firm Boehringer Ingelheim.
Venture capital fund Gründerfonds Ruhr co-led the round, which included public-private partnership High-Tech Gründerfonds and NRW.Bank, the state development bank of North Rhine-Westphalia. Boehringer Ingelheim invested through its Boehringer Ingelheim Venture Fund.
Abalos is leveraging its Fast Evolution platform to develop cancer immunotherapies that employ a specific arenavirus strain thought to provoke anti-tumour immune responses by…
